Chinese regulators' 2026 approval list is no longer dominated by imported brands. Of the innovative drugs approved in the first three quarters of this year, roughly 80% were domestically developed, according to figures carried by Beijing Daily. For a patient abroad who is running out of standard options, that single number matters more than any hospital ranking. It means the newest molecules are increasingly invented by Chinese companies, filed in China first, and therefore prescribable in Chinese hospitals before regulators in the United States, Europe or Japan have finished reviewing the same drug. This guide looks at where that China-first window comes from, which therapy categories are most likely to sit inside it, and what the legal access routes and realistic waiting cycles look like for an international patient.
Why new drugs now reach Chinese patients first
The same report describes an ecosystem that produces that time gap rather than merely importing one. Between January and June 2026, Chinese innovators signed 81 outbound licence deals worth approximately US$110 billion in total, a record. China's drug clinical trials topped 5,000 for the first time in 2025, and roughly one third of all newly initiated trials worldwide in the first quarter of 2026 were started in China. In the first half of 2026, Chinese companies occupied eight of the top ten global pharmaceutical mega-deal positions.
Read literally, those figures do not mean a drug is available in Boston, London or Sydney the day a licence is signed. A licence-out transfers rights in other territories; the partner still has to run its own regulatory review, negotiate pricing and win hospital contracts there. So the deal flow tells you something more useful for a patient: the molecule's originator, its earliest comparative data and its first commercial supply are all sitting in China, and the overseas version is still in a queue. That queue is the window.
Which therapies are most likely to sit in the China-first window
The categories where a foreign patient is most often told "this exists here, not yet there" are the ones where Chinese developers are not just first-in-class but first-to-market.
Cell therapy, including CAR-T
Chimeric antigen receptor T-cell therapy is the clearest example of a treatment whose practical availability is uneven across borders. The Chinanews Shanghai report on how Shanghai structures care for international patients explicitly names CAR-T among the treatment scenarios that private institutions are building their international services around. Our CAR-T therapy in China page and the cost breakdown cover the practical detail, including how a quoted price is assembled.
Bispecific antibodies and newer immunotherapy backbones
Bispecific and multi-specific antibodies are a second area where Chinese developers have moved quickly through registration, and where an overseas patient may find the same drug class at a different stage of availability in different countries. The honest framing: treat this as a category to verify drug by drug, not a list you can rely on from a news headline.
Chemotherapy-free cancer regimens developed in China
The Beijing Daily piece highlights a gastric cancer drug built around a "chemotherapy-free" approach, self-developed by a Chinese company and described as the world's first of its kind. This is the type of protocol that changes treatment conversations abroad, because it is not a me-too version of an existing standard — it is the original. See how systemic therapy is organised for international patients on our cancer treatment in China page.
Particle therapy as a parallel access story
Some patients come for technology availability rather than a drug — proton and heavy-ion centres, described in our proton therapy guide and service page. Same logic, different capital equipment.
What is actually available: how to verify before you book
Neither of the reports behind this article publishes a drug-by-drug list that a foreign patient could act on, and no responsible guide should invent one. Availability resolves into three separate questions:
- Is the product approved in China, and for which indication? Check the regulator's approval record for the specific drug and line of therapy, not a press release about the molecule in general.
- Does the named hospital stock it and accept international patients for it? A national approval does not guarantee that a particular centre's pharmacy carries it, or that its department takes overseas self-pay cases in that disease.
- Does your disease fall inside the label, or outside it? If the answer is "outside", the realistic route is a trial, not a clinic visit.
That verification is exactly what a pre-trip evaluation is for, and it is why we recommend sending records before you book flights rather than after.
Three routes foreign patients use, compared
Shanghai has been building the delivery side of this for years: international medical pilots in 2020 and 2023, a local standard for international medical services implemented in 2024, and continued inclusion of international medical supply in the June 2026 services-sector plan for the 15th Five-Year period, per the Chinanews report.
| Access route | How the medicine is obtained | Payment and insurance | Scheduling and waiting cycle | Best suited to |
|---|---|---|---|---|
| Public hospital international medical services | Approved drug prescribed by a specialist after in-person review | Usually self-pay; insurer reimbursement handled at home | Most demand-constrained; appointments need advance booking | Patients who want the highest-volume oncology centre for their disease |
| Private and international hospitals (IHH's Baihui Medical and Jiahui Health are named in the report) | Approved drug within the institution's service set, including CAR-T scenarios | Direct billing reported with international insurers; one private hospital licensed in 2025 works with around 60 global insurers, so the patient does not advance the cost | Bed occupancy of roughly 26%–46% at some private hospitals indicates bookable spare capacity | Patients who need English-language coordination, direct billing and a scheduled rather than queued slot |
| Clinical trial at a Chinese site | Investigational drug supplied per protocol | Covered under the study; travel and ancillary costs are not | Longest path: screening windows, eligibility criteria and protocol visit schedules | Patients whose drug is not yet approved anywhere |
| Personal import or filling the prescription at home | Not a route | — | — | Not recommended; these therapies are usually administered under supervision |
For facility-level comparison, see best international hospitals in Shanghai and our hospital directory.
The legal pathway, step by step
A workable sequence for a foreign patient looks like this. Collect the recent pathology report, imaging files, treatment history and current medications. Have them translated into Chinese. Submit them for a written pre-consultation evaluation so a physician can judge whether the specific product or protocol is even applicable to your case. Once a named hospital and department are confirmed, arrange entry documentation — our China medical visa guide covers the options. Book the appointment, attend in person, receive the plan and the written quotation, then schedule treatment and monitoring. Finally, arrange how follow-up and adverse-event management will work once you are home.
Four things decide how long that takes: whether the hospital holds the drug on formulary, whether your diagnosis matches the approved indication, whether your insurer has a direct-billing contract with that institution, and how the department sequences complex procedures — cell therapy and infusion protocols add their own scheduling steps. Any overall estimate should be treated as planning assumption rather than a promise: patients should plan in months, not days, and confirm dates with the treating centre before committing to travel. Prices likewise come from the hospital as a written quote; nothing in these reports supports an international-patient price list for a specific drug.
Risks and limits worth stating plainly
A China-first approval is not the same thing as a home-country guideline. Indications, lines of therapy and dosing may differ from what your oncologist knows. Much of the supporting evidence is generated in Chinese trial populations. Reimbursement at home is rarely automatic. Continuity of care after you fly back — who manages a late toxicity, who reads the next scan — is the most common weak point in cross-border treatment. Language and record transfer are solvable, but only if arranged in advance.
This page is general information, not medical advice, and no outcome is promised. Any specific treatment plan must be assessed in person by a licensed physician.
Is a China-first medicine worth pursuing?
Worth a serious look when: standard lines at home are exhausted; the drug you want has a Chinese approval and a named hospital with a documented international-patient pathway for your disease; a direct-billing route or private funding exists; and your local team is willing to receive records and manage follow-up.
Poor timing when: the drug is only in early-phase research with no open eligibility for non-residents; your performance status makes long-haul travel risky; or the only version available abroad differs materially and your physician would not support switching mid-treatment.
Get a pre-trip answer on your specific drug
If you are weighing a medicine that is approved in China but not yet where you live, the useful first step is not a flight booking — it is a documented check on that product, that indication and that hospital. Submit your case at /case-evaluation and OriEast will review it, arrange certified translation, secure the appointment and coordinate the visit and follow-up on the ground in Shanghai. For open questions about cost, insurance direct billing or timelines, use the inquiry form or reach us through the contact page.